Stemline Therapeutics (STML) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Stemline Therapeutics Reports Third Quarter 2015 Financial Results
November 6, 2015 8:00 AM ESTNEW YORK, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML) today reported financial results for the quarter ended September 30, 2015.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "During the third quarter, we made significant progress on many fronts as we continue to advance our clinical programs forward. We are actively enrolling patients, and opening additional sites, in the expansion stage of our ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm, BPDCN. We look forward to sharing clinical updates from both the lead-in and initial expansion stages of this trial... More
Stemline Therapeutics Reports Third Quarter 2015 Financial Results
November 6, 2015 8:00 AM ESTNEW YORK, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML) today reported financial results for the quarter ended September 30, 2015.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "During the third quarter, we made significant progress on many fronts as we continue to advance our clinical programs forward. We are actively enrolling patients, and opening additional sites, in the expansion stage of our ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm, BPDCN. We look forward to sharing clinical updates from both the lead-in and initial expansion stages of this trial... More
